| NR5A1 | Steroidogenic factor 1 | Cutaneous Melanoma (3.14%) | Prostate Cancer, NOS (16.92%) |
| CSF3R | Granulocyte colony-stimulating factor receptor | Penile Cancer (14.29%) | Ovarian Cancer (5.71%) |
| NFKB2 | Nuclear factor NF-kappa-B p100 subunit | Cholangiocarcinoma (100%) | Prostate Cancer, NOS (7.69%) |
| TNK2 | Activated CDC42 kinase 1 | Myelodysplasia (5.56%) | Prostate Cancer, NOS (21.54%) |
| UBC | Polyubiquitin-C | Endometrial Cancer (2%) | Prostate Cancer, NOS (12.31%) |
| PIK3R2 | Phosphatidylinositol 3-kinase regulatory subunit beta | Small Bowel Cancer (5.56%) | Prostate Cancer, NOS (13.85%) |
| IDE | Insulin-degrading enzyme | Endometrial Cancer (3.78%) | Prostate Cancer, NOS (7.69%) |
| PSMB3 | Proteasome subunit beta type-3 | Adrenocortical Carcinoma (0.99%) | Breast Cancer, NOS (18.75%) |
| GRM7 | Metabotropic glutamate receptor 7 | Ovarian/Fallopian Tube Cancer, NOS (14.29%) | Prostate Cancer, NOS (23.08%) |
| THRA | Thyroid hormone receptor alpha | Colorectal Adenocarcinoma(2.91%) | Breast Cancer, NOS (18.75%) |
| MED1 | Mediator of RNA polymerase II transcription subunit 1 | Cervical Cancer (4.6%) | Breast Cancer, NOS (31.25%) |
| THRB | Thyroid hormone receptor beta | Cutaneous Melanoma (5.23%) | Prostate Cancer, NOS (21.54%) |
| NCS1 | Neuronal calcium sensor 1 | Endometrial Cancer (0.59%) | Prostate Cancer, NOS (13.85%) |
| NR3C2 | Mineralocorticoid receptor | Ovarian/Fallopian Tube Cancer, NOS (14.29%) | Prostate Cancer, NOS (15.38%) |
| TUB | Tubby protein homolog | Endometrial Cancer (4.08%) | Prostate Cancer, NOS (9.23%) |
| IL2 | Interleukin-2 | Cutaneous Melanoma (1.05%) | Prostate Cancer, NOS (7.69%) |